8-K: Viridian Therapeutics Announces Positive Long-Term Data from Veligrotug Phase 3 THRIVE Trial for Thyroid Eye Disease

Viridian Therapeutics reports that 70% of patients treated with veligrotug in the THRIVE trial who showed a proptosis response at week 15 maintained that response at week 52.

Summary

• Viridian Therapeutics announced positive long-term durability data from the THRIVE phase 3 clinical trial of veligrotug for active thyroid eye disease (TED).
• The THRIVE trial evaluated 5 infusions of veligrotug or placebo every three weeks, with primary analysis at week 15 and follow-up through week 52.
• 70% of veligrotug patients (21/30) who were proptosis responders at week 15 maintained their proptosis response at week 52.
• Maintenance of response is defined as at least a 2-millimeter reduction in proptosis compared to baseline at week 52, without worsening in the fellow eye.
• The safety profile remained consistent during the follow-up period, with most adverse events resolving by week 52.
• Veligrotug met all primary and secondary endpoints in the THRIVE and THRIVE-2 trials for active and chronic TED, respectively, announced in late 2024.
• The company is actively preparing for a potential U.S. commercial launch in 2026.
• The Biologics License Application (BLA) submission for veligrotug is on track for the second half of 2025.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial data and outlines a clear path to potential commercialization, indicating a favorable outlook for Viridian Therapeutics.

Positives

• Veligrotug demonstrated a durable response in a significant percentage of patients with active TED.
• The safety profile of veligrotug remained consistent throughout the trial, with most adverse events resolving by week 52.
• Veligrotug met all primary and secondary endpoints in both the THRIVE and THRIVE-2 trials.
• The company is on track to submit the BLA in the second half of 2025.
• Veligrotug has the potential to improve patient experience with a differentiated dosing regimen.

Risks

• The forward-looking statements are subject to material risks and uncertainties, including the potential utility, efficacy, and safety of Viridian's product candidates.
• Clinical trial results may not be representative of future trials.
• Regulatory approvals may be delayed or not obtained.
• Competition from other therapies or products could impact commercial success.
• The company's intellectual property position could be challenged.

Future Outlook

Viridian anticipates submitting the BLA for veligrotug in the second half of 2025 and is preparing for a potential U.S. commercial launch in 2026. The company believes veligrotug has the potential to be a market-leading TED therapeutic, if approved.

Management Comments

• Steve Mahoney, Viridian's President and CEO, stated that the durability and safety data reinforce veligrotug's strong clinical profile.
• Management believes veligrotug has the potential to be the treatment-of-choice for patients living with TED.

Industry Context

The announcement highlights Viridian's progress in the competitive TED treatment market, where IGF-1R inhibitors have already achieved significant commercial success. Veligrotug aims to improve patient experience with a shorter infusion time and fewer infusions compared to the currently approved IGF-1R inhibitor.

Comparison to Industry Standards

• The document compares the durability of veligrotug to Tepezza, another treatment for TED.
• Tepezza's prescribing information shows that 53% of proptosis responders maintained their response at week 72, while the THRIVE trial showed 70% of proptosis responders maintained their response at week 52.
• Cross-trial comparisons should be avoided due to the lack of head-to-head clinical trial data.

Stakeholder Impact

• Positive results could lead to improved treatment options for patients with thyroid eye disease.
• Successful commercialization of veligrotug could increase shareholder value.
• The company's progress may enhance its reputation and attract potential partners.

Next Steps

• Submission of the Biologics License Application (BLA) for veligrotug in the second half of 2025.
• Preparation for a potential U.S. commercial launch of veligrotug in 2026.
• Continued development of VRDN-003 as a potential best-in-class subcutaneous therapy for TED.

Key Dates

Keywords

veligrotug, thyroid eye disease, TED, THRIVE trial, VRDN-001, proptosis, diplopia, IGF-1R, clinical trial, BLA submission, Viridian Therapeutics